Toxicities of Immunosuppressive Treatment of Autoimmune Neurologic Diseases

Author(s): Enrico C. Lallana, Camilo E. Fadul.

Journal Name: Current Neuropharmacology

Volume 9 , Issue 3 , 2011

Become EABM
Become Reviewer

Abstract:

In parallel to our better understanding of the role of the immune system in neurologic diseases, there has been an increased availability in therapeutic options for autoimmune neurologic diseases such as multiple sclerosis, myasthenia gravis, polyneuropathies, central nervous system vasculitides and neurosarcoidosis. In many cases, the purported benefits of this class of therapy are anecdotal and not the result of good controlled clinical trials. Nonetheless, their potential efficacy is better known than their adverse event profile. A rationale therapeutic decision by the clinician will depend on a comprehensive understanding of the ratio between efficacy and toxicity. In this review, we outline the most commonly used immune suppressive medications in neurologic disease: cytotoxic chemotherapy, nucleoside analogues, calcineurin inhibitors, monoclonal antibodies and miscellaneous immune suppressants. A discussion of their mechanisms of action and related toxicity is highlighted, with the goal that the reader will be able to recognize the most commonly associated toxicities and identify strategies to prevent and manage problems that are expected to arise with their use.

Keywords: Immunosuppressive therapy, toxicity, auto-immune neurologic disease, multiple sclerosis (MS), peptic disease, CNS vasculitides, Cyclophosphamide therapy, myasthenia gravis (MG), proximal myopathy

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 9
ISSUE: 3
Year: 2011
Page: [468 - 477]
Pages: 10
DOI: 10.2174/157015911796557939
Price: $58

Article Metrics

PDF: 5